You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.
The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.
The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.
Iceni Diagnostics aims to deliver a rapid, point-of-care test that could differentiate the virus from more common flu strains using artificial glycan receptors.
The QiaStat-Dx Respiratory SARS-CoV-2 Panel can detect and differentiate SARS-CoV-2 and 21 other respiratory pathogens in symptomatic patients.
The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.
The company said it expects to launch the Verigene II system with respiratory and gastrointestinal assays in the middle of this year.
Qiagen, which is also developing a single-plex qRT-PCR assay for SARS-CoV-2, said it will have a syndromic panel including targets for the virus ready this month.
The company said the funding will support international expansion of its FebriDx rapid point-of-care test and its US clinical trial.
The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.